Kymera’s pain could be Priovant’s gain
Pfizer’s Irak-4 inhibitor PF-06650833 definitely, definitely doesn’t work in hidradenitis suppurativa, but there’s at least partly better news for Priovant.
Newamsterdam braves the Spac track
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
The Spac story departs from the script
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
Sumitomo takes out Urovant, and Myovant beckons
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
